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Abstract: One of the most challenging goals in pharmacological research is overcoming the Blood
Brain Barrier (BBB) to deliver drugs to the Central Nervous System (CNS). The use of physical
means, such as steady and alternating magnetic fields to drive nanocarriers with proper magnetic
characteristics may prove to be a useful strategy. The present review aims at providing an up-to-date
picture of the applications of magnetic-driven nanotheranostics agents to the CNS. Although well
consolidated on physical ground, some of the techniques described herein are still under investigation
on in vitro or in silico models, while others have already entered in—or are close to—clinical
validation. The review provides a concise overview of the physical principles underlying the behavior
of magnetic nanoparticles (MNPs) interacting with an external magnetic field. Thereafter we describe
the physiological pathways by which a substance can reach the brain from the bloodstream and
then we focus on those MNP applications that aim at a nondestructive crossing of the BBB such as
static magnetic fields to facilitate the passage of drugs and alternating magnetic fields to increment
BBB permeability by magnetic heating. In conclusion, we briefly cite the most notable biomedical
applications of MNPs and some relevant remarks about their safety and potential toxicity.
Keywords: magnetic nanoparticles; targeting; delivery; central nervous system; blood brain barrier
1. Introduction
Already in 2006, the World Health Organization (WHO) published a report on brain disorders
and their future impact [1]. According to them, brain disorders constitute 12% of total deaths globally,
being cerebrovascular diseases responsible for 85% of the deaths due to brain disorders. Together
with dementia, such pathologies are strictly related to people aging. As far as dementia is considered,
they estimated that, globally, 24.3 million people have dementia today, with 4.6 million new cases
annually. Numbers of people affected will double every 20 years to 81.1 million by 2040. Most people
with dementia live in developing countries: 60% in 2001 rising to an estimated 71% by 2040.
The economic costs of dementia are enormous, and include “formal care” (health care, social and
community care, long-term residential or nursing-home care) and “informal care” (unpaid care by
family members, including their lost opportunity to earn income). According to [2] direct costs are
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about 60% of the total, and the annual European (EU27 + Iceland, Norway and Switzerland) cost for
dementia was estimated to be about €105 billion (PPP) in 2010.
Currently there are no treatments to cure dementia. Some drugs (cholinesterase inhibitors),
in some cases, but not all, temporarily decelerate the progressive cognitive decline that occurs in
Alzheimer’s Disease (AD), and maybe in other forms of neurodegenerative dementia. These drugs
act on the symptoms but not on the disease itself; they make only a small contribution to
maintaining function.
In the coming next years, innovative approaches in drug delivery to treat Central Nervous System
(CNS) diseases are necessary as pathologies such as stroke and Neurodegenerative Diseases (NDs) are
becoming an important medical and social issue due to the aging of the general population, and the
related economic costs of both therapies and care.
When available, current pharmacological treatment is mainly based on the systemic delivery
of active and effective substances, whose effects are severely limited by poor pharmacodynamic
properties and intake limitations due to the Blood Brain Barrier (BBB).
Overcoming the BBB and properly deliver the drug cargo in the CNS is therefore the first
requirement for an effective therapy, and both chemical and physical approaches have been proposed:
See [3,4] for a short summary of the latter.
The present review focuses on the use of magnetic fields in promoting the crossing of the BBB
and the driving of the therapeutic agents in the CNS. Current clinical applications, their specific safety
issues and future prospects are also briefly outlined.
2. Methods
PRISMA guidelines recommendations were followed for the search, the selection and the reporting
of the relevant papers (http://www.prisma-statement.org). The following scientific reference resources
were used: PubMed and MEDLINE, as we focused on biomedical applications. Data mining was
performed through articles published up to October 2017 (time limit), using combinations of the
following MeSH keywords: nanoparticles, magnetic, central nervous system, blood brain barrier, and
non-MesH keywords: magnetofection, magnetoporation. Searches were limited to articles published
in English. We used a query with the following logical combination of the keywords:
nanoparticles AND magnetic AND (central nervous system)
OR
nanoparticles AND magnetic AND (blood brain barrier)
OR
magnetoporation AND (central nervous system)
OR
magnetofaction AND (central nervous system).
Cited literature supports the discussion of the role of magnetic targeting/delivery in CNS, but it
is not meant to be exhaustive. In our data mining, most of the included research and review articles
were published after 2015.
3. Results
All the query results were pooled together, removing the duplicates. Resulting references were
screened to keep only the papers answering with the following criteria: description of biomedical CNS
applications of nanoparticles steered by magnetic force to be targeted on a defined space position or
to deliver drugs or therapeutic compounds. Other biomedical applications (e.g., cells destruction by
hyperthermia, cells migration/scaffolding) were excluded.
Further references were retrieved manually by reviewing the bibliographies of the
relevant publications.
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Five hundred and fifty-seven (557) papers were retrieved through database searching and 37 more
by looking at the references in the final selection. The number of records selected for the qualitative
synthesis was reduced to 76 after the removal of duplicate entries and the selection of relevant papers
by reading titles and abstract content.
The selected literature about magnetic targeting/delivery in the CNS was classified into seven
main groups:
• reviews [4–21];
• in silico modeling [22–25];
• BBB crossing under Static Magnetic Field (SMF) influence [26–37];
• Alternating Magnetic Field (AMF) applications for targeting/delivery [38–43];
• magnetofection [44–49];
• applications for CNS disease:
1. brain tumors [50–53],
2. neuroAIDS [54–59],
3. wireless Deep Brain Stimulation (DBS) [60–67],
4. stroke [68,69],
5. NDs [70–75];
• CNS toxicity [76–79].
4. Discussion
4.1. General Properties of Magnetic Nanoparticles
In biomedicine, smart drug carrier or smart nanoparticle (NP) design is an evolving technology
of outstanding relevance, as their size is comparable with those of cells (<100 µm), viruses (<450 nm),
proteins (<100 nm) and genes (length < 100 nm), thus opening the possibility of external manipulation
of fundamental biological processes [9]. An important advantage of NPs in improving drug delivery is
also their superior bioavailability due to a prolonged presence in the blood circulation and their high
surface-to-volume ratio which enhances the contact between the drug and the body fluids [6].
The enhancement of effective drug delivery to the target achieved by the addition of magnetic
energy using NPs sensitive to magnetic fields has been widely explored in recent years. The idea is
almost 60 years old, since it had already been proposed by Freeman [80] in 1960, but the necessary
technology has only recently been developed. Many technical issues still have to be solved before
routine application in clinical settings on human patients is possible. Currently, only a very small
number of clinical trials are ongoing and very few of them deal with CNS diseases, due to the additional
difficulty represented by BBB trespassing [18].
NPs exhibiting magnetic properties are called magnetic nanoparticles (MNPs) and their capability
of creating temporary pores in the membranes of the cell—as is the case in the BBB endothelium—to
improve targeting and delivery is called magnetoporation [4]. MNPs are already employed in many
biomedical applications [4–21]:
• magnetic enhancing contrast agents;
• magnetic hyperthermia and heating;
• magnetic labeling and separation;
• magnetic vectors.
As MNPs can be used in both in diagnostic and therapeutic applications, even jointly, they are
often considered the prototypical tool for theranostic applications [18]. In particular, drug delivery
with the aid of magnetic fields has been termed magnetic drug targeting [6] and several steps have to
be pursued to reach this goal [4]: Manufacturing MNPs with a sufficient magnetic coupling, assessing
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their stability and bioavailability, designing a SMF to push/pull MNPs near a planned location (target),
optionally using an AMF or other mechanisms such as ultrasounds [81–83] to control/enhance the
delivery of the drug.
When systemic (e.g., intravenous) administration is considered, MNP characteristics (size, shape,
surface charge, coating, magnetic properties) have to be specifically tailored for the planned clinical
application [18]. In particular, MNP optimum size and most performing magnetic properties heavily
depend on the physiological characteristics of the target. Simulations [22,23] generally consider three
forces acting on MNPs circulating in blood vessels: magnetic drift, diffusion and blood advection.
Hence, three regimes are possible:
• magnetic force dominance;
• blood velocity dominance;
• boundary layer formation (when magnetic and drag force are comparable).
Only in this third case, a zone of enhanced concentration of MNPs can be established in a steady
state condition at the interface between tissues and blood. If MNPs are retained near the target long
enough they may be internalized by the cells. The occurrence of this most favorable regime critically
depends on relative values of three non-dimensional parameters:
• the Magnetic-Richardson number, that represents the ratio between magnetic and drag forces;
• the mass-Péclet number, that represents the ratio between advection and diffusion rates;
• the Renkin-reduced diffusion coefficient, that represents the ratio between the diffusivity in the
tissue and the total diffusivity in the blood.
Size, shape and coating can alter magnetic forces and resistance by orders of magnitude:
exceedingly small particles experience an insufficient magnetic force and too big ones encounter
too much resistance in the tissue [24,25]. In general, the field strength should be of the order of
200–700 mT with gradients of about 8–100 T/m, depending on the blood flow (rate ranging from
10 cm/s in arteries to 0.05 cm/s in capillaries) [9]. In the human brain, the working distance (up to
30–50 cm from the magnet surface) and the safety restrictions of the magnetic field strength (8 T adults,
4 T children) limit the applications of MNPs in clinical settings [18]. Magnetic targeting is likely to be
more effective for targets near the surface of the body and in regions of slower blood flow [84].
Essentially, many interconnected factors contribute to influence the effectiveness of MNP targeting
and delivery [6,9,15,16,19]: the already cited inherent MNP properties—size, magnetic properties,
coating, functionalization, biocompatibility (i.e., toxicity)—but also many extrinsic factors—such
as the chemical properties of the loaded drugs, the strength, the gradient and the geometry of
the magnetic field, the physical (e.g., viscosity) and physiological (e.g., flux) characteristics of the
environment in which MNPs move and finally their bioavailability connected to cell uptake and
unwanted internalizations.
Moreover, inherent NP properties are also responsible for the stability of their aqueous suspension.
MNPs are generally produced as a colloidal ferrofluid: a suspension of magnetic nanoparticles in
aqueous fluids with concentrations of about 1015–1017 particles/mL. Their stability depends on the
balance among forces—van der Waals, dipole-dipole, steric, thermal and electrostatic—between
the particles and the surrounding solvent molecules. A biocompatible polymeric layer coating
(e.g., PEG, polyethylenimine, polylysine, polyacrylic acid) has been demonstrated to improve the
stability of MNPs [16]. In contrast, without a proper coating and because of their large hydrophobic
surface to volume ratio, MNPs have a greater tendency to aggregate, but on the other hand the large
surface-volume ratio provides many chemical sites to conjugate bioactive molecules and functionalize
MNPs for many different applications [7,8,12,13,20]. In this regard, special attention to safety has to
be paid since the unwanted agglomeration of MNPs can result in blood vessels clotting. An efficient
strategy to avoid such a risk is to use superparamagnetic MNPs (see below).
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4.2. Interplay between MNPs and Magnetic Fields
All materials exhibit magnetic properties that arise from the distribution of electrons spinning
around their atomic nucleus. In each atom, nucleus and electrons create a system of interacting
magnetic dipoles that cause atoms to act as a permanent dipole provided they do not completely
counterbalance because of a symmetric atomic configuration (e.g., iron [9]). A permanent dipole is
characterized by its magnetic moment, which represents the torque it experiences when interacting
with an external magnetic field. When an external magnetic field (H) is applied to a given material,
at microscopic level the atomic dipoles tend to align with the field direction, causing a macroscopic
measurable magnetic moment. Magnetization M or magnetic moment per unit volume is proportional
to H through a non-dimensional coefficient (χ) called magnetic susceptibility [9]:
→
M = χ
→
H (1)
If χ is weakly negative (<−10−3) the material is diamagnetic, if it is slightly positive (<10−1) the material
is paramagnetic and if it is largely positive the material is ferromagnetic (>103). For diamagnetic and
paramagnetic materials, the relationship between H and M is generally linear, while ferromagnetic
materials exhibit some magnetic hysteresis, that is the material could show residual M also after
turning off H [9].
In general, magnetization does not increase indefinitely with H due to the limited number
of dipoles that can interact constructively under its influence: when this limit is asymptotically
approached we get the saturation of the magnetization (MS) [9].
Ferromagnetic materials become paramagnetic over a critical temperature called Curie
temperature (e.g., 1043 K for iron) and may become superparamagnetic provided their size is lower
than a critical value called superparamagnetic diameter [6]. The superparamagnetic diameter has to be
smaller than the diameter of the specific material single magnetic domain—in general, less than 50 nm,
depending on the material. In this sense, superparamagnetism can be considered as an emergent
property of ferromagnetic nanoparticles, where each MNP can be though as the carrier of a single giant
magnetic moment, the sum of the individual magnetic moments of the atoms forming it. Normally,
these ‘macro-spins’ can randomly flip direction under the influence of temperature and the average
magnetization is zero over time. However, in these conditions, an external magnetic field is able to
magnetize the nanoparticles, similarly to what happens with a paramagnet, but with χ well higher
than the paramagnetic ones [6].
Such properties are satisfied by Iron Oxide NPs (IONs), highly magnetizable MNPs containing
iron oxide particles composed of magnetite (Fe3O4) or maghemite (γ-Fe2O3). They are often called
Superparamagnetic Iron Oxides Nanoparticles (SPIONs) or Ultra-Small Superparamagnetic Iron
Oxides Nanoparticles (USPIONs) on the basis of their size (>50 nm or <50 nm, respectively) [33].
Both oxides are ferromagnetic with very similar structures and properties, although magnetite
has a larger MS than maghemite (90–100 emu/g vs. 60–80 emu/g), a lower Curie temperature (850 K
vs. 948 K) and a lower superparamagnetic diameter (25 nm vs. 30 nm). They both exhibit chemical
stability under physiological condition, low toxicity and high magnetic moments.
A variety of methods to synthesize IONs have been described: co-precipitation, thermal
decomposition, hydrothermal, solvothermal, sol-gel, microemulsion, ultrasound irradiation and
biological procedures. One of the simplest and most commonly employed methods is the
co-precipitation of Fe2+ and Fe3+ from aqueous salt solutions by base addition. The salts used,
the Fe2+ to Fe3+ ratio, pH and ionic strength of the media influence the final size, the shape and the
composition of the resulting MNPs [6].
IONs can be directly used in targeting application or in combination with other nanovectors,
such as polymeric nanodroplets, as those described in Figure 1 and presented in [85].
As already stated, working with superparamagnetic particles is highly recommended as MNPs can
respond with a high magnetization, reaching MS under the influence of an external field. Additionally,
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when the field is turned off MNPs lose their magnetic properties avoiding the risk of reciprocal
attraction and agglomeration [9].
IONs are thought to be well tolerated as they gradually are degraded to Fe3+ that is integrated
into the cellular iron deposits for metabolic processes and its excess can be eventually eliminated [78].
Notably, it is to be paid particular care to the iron concentration in the brain as toxicity and apoptosis
could arise due to the great sensitivity of the CNS to iron concentration [76,79].
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ܨ஽ in the fluid where MNPs are moving with a velocity ݒ (ߟ being the viscosity of the fluid and 
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Hydrodynamic radius ݎு can be larger (up to 4× or more) than particle radius especially if 
MNPs have been coated or functionalized [9]. During blood circulation a corona of proteins and 
other particles could be attracted by MNPs, thus changing their characteristics as bioavailability 
and interactions with cells [78]. A tradeoff has to be paid for size as small MNPs do not aggregate 
and more easily cross biological barriers, but they respond less to magnetic force (see Equations (2)–
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Although in principle magnetic targeting should be feasible with any accuracy, currently there 
are no systems capable of a precise deep focusing. A general limit for the creation of a magnetic 
Figure 1. Schematic representation of two strategies for drug delivery through magnetic nano-carriers.
(A) The magnetic element is the core of the nanoparticles, while the active compound is linked to the
protective coating surfacing the core; (B) In this case, the magnetic element consists of a number of
iron nanoparticles attached to the surface of a nano-bubble structure that can be internally loaded with
drug compounds.
Using an external magnetic field B acting on a MNPs of volume V, density ρ and magnetic
moment M we obtain a magnetic ‘driving force’ [4,7]:
→
FM =
(→
m·∇
)→
B , (2)
→
m = ρV
→
M. (3)
High static fields are needed to have a high magnetization of the MNPs (up to MS) but also high
gradients to push/pull them are required. The magnetic force should contrast the drag force FD in
the fluid where MNPs are moving with a velocity v (η being the viscosity of the fluid and rH the
hydrodynamic radius of the nanoparticle) [4]:
FD = 6piηrHv. (4)
Hydrodynamic radius rH can be larger (up to 4× or more) than particle radius especially if
MNPs have been coated or functionalized [9]. During blood circulation a corona of proteins and
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other particles could be attracted by MNPs, thus changing their characteristics as bioavailability and
interactions with cells [78]. A tradeoff has to be paid for size as small MNPs do not aggregate and
more easily cross biological barriers, but they respond less to magnetic force (see Equations (2)–(4)
FM ∼ r3 vs. FD ∼ r). In any case, superparamagnetic radius gives a superior limit to ION size.
Although in principle magnetic targeting should be feasible with any accuracy, currently there
are no systems capable of a precise deep focusing. A general limit for the creation of a magnetic static
trap had already been demonstrated by Samuel Earnshaw in 1839. Relative focusing is possible only
using dynamic magnetic fields [18]. Moreover, B rapidly decreases when penetrating living tissues,
thus dramatically affecting the efficiency of the delivery to deep targets, located far away from the
surface of the body. As a result, even if several in vitro and animal studies have been reported, clinical
applications are still very challenging due to difficult targeting in deep tissues (namely >2 cm depth)
and because particles exhibit poor retention when the external magnetic field is turned off [9].
Summarizing, drugs encapsulated or attached to MNPs are relatively simple to synthetize,
penetrate easily in living tissues, have a low toxicity (good biocompatibility) and can be remotely
controlled by external non-invasive magnetic fields. With particular reference to the SNC,
the advantages of magnetic drug targeting in the brain are: noninvasiveness, no direct contact, efficient
control of drug delivery; cons are: possible accumulation and cytotoxicity, possible aggregation
and embolization, limited bioavailability to brain due to absorption by other organs (liver, kidneys),
fast decay of the magnetic field from surface.
Some of the downsides could be turned to advantages, for example enhanced toxicity
against tumor cells or closing of the blood vessels by clotting if needed (e.g., arteriovenous
malformation, hemorrhages).
4.3. BBB: Critical Issues and Trespassing by MNPs
Despite the extended surface area of about 20 m2 of the 100 billion capillaries feeding the human
brain [6], many substances have very limited diffusion from blood to neurons because of the existence
of the BBB and blood-Cerebro Spinal Fluid (CSF) barrier (Figure 2).
The endothelial cell layer of the capillaries of the brain parenchyma has features which are
unique in the human body, in that it presents tight junctions between adjacent cells and no
fenestrations. This causes an increased overall Trans-Endothelial Electrical Resistance (TEER), as high
as 2000 Ω·cm2 [9]. Moreover, brain endothelial cells have a reduced transcellular general permeability
(scarce endocytotic vesicles) and many ATP proteins (e.g., P-glycoprotein and multidrug resistance
protein) that act as efflux pumps keeping in blood circulation most of the molecules. As a consequence,
up to the 98% of the substances—including therapeutic agents—cannot reach the brain [6].
This highly efficient defense mechanism allows exceptions only for those elements needed for
brain functioning (e.g., glucose, amino acids) admitting four main ways [76] to trespass the barrier
(Figure 3):
• passive transcellular diffusion (only O2, CO2 and small lipid-soluble substances),
• Carrier protein-Mediated Transport (CMT),
• Receptor-Mediated Transcytosis (RMT),
• Adsorptive-Mediated Transcytosis (AMT).
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Figure 2. Comparison between the structure of the Blood-Brain Barrier (BBB) and the blood-CSF
barrier. (Left) BBB separates the lumen of the brain capillaries from the brain parenchyma. The main
contribution to the BBB property of reduced permeability comes from the tight junctions (drawn in
violet) among endothelial cells lining the capillaries. The so-called neurovascular unit also comprises
the pericytes, a basement membrane surrounding both pericytes and endothelial cells and astrocyte
end-feet processes from nearby astrocytes. As well as the undisputed role of the tight junctions in
sealing the interendothelial cleft, all the elements of the neurovascular unit are likely to contribute
to some extent to the augmented selectivity of the BBB. That said, their role is still controversial;
(Right) The Blood-CSF barrier is found in the choroid plexus of each ventricle of the brain. Unlike the
endothelium in the brain parenchyma, capillaries of the choroid plexus have no tight junctions and
are fenestrated. However, the choroid plexus is elimited overall by a monolayer of tight-junctioned
epithelial cells. This pa ticular pitheliu is in direct continuity with th ependymal layer lining the
ventricle, though the rest of the ependymal layer is much more permeable. Therefore, un ike the BBB,
the blood-CSF barrier is located at epithelial level, while capilla ies ar relatively leaky and permeable
to small mol cules, thus all wing, among other processe , the rapid elivery of wate through the
bloodstream to t e surroundi g epi lial cells for CSF production in the choroid pl xus. Similarly,
to what ca be found in other tissues of the body, also in the choroid lexus pericytes and a ba m nt
membrane wrap around the endothelial cells. Although in principle both the barriers serve the same
defensive purpose for the CNS, their distinct structure allows the interchange of different substances
between bloodstream and brain. (Upper part) Top view; (Lower part) Section view.
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Figure 3. Schematic enumeration of the many pathways which a compound can use to cross the
blood-brain barrier, de e i on its chemico-physical properties. (A) Drugs can cross the barrier
simply by passive di fusi t ey are suffic ently lipid solub e (or have been made lipoph lic by
appropriate che ic l modifications); (B) Carrier protein-M diated active Tr nsport (CMT) can allow
many essential compounds such as glucose and amino acids to enter the endothelial cytoplasm and
then be released into the brain at the abluminal side. In addition, artificial compounds mimicking
those endogenous ligands have been developed to take advantage of the carrier-mediated transport
mechanisms; (C) Drugs or even NPs can enter the brain through a paracellular route only when the
tight junction system is disrupted. In particular, BBB permeability can be temporarily induced in several
ways: by local temperature increases (38–39 ◦C), by osmotic alterations (e.g., infusion of hypertonic
solutions of mannitol), by adenosine receptor activation, by Focused Ultrasound (FUS) bombardment
o by electromagnetic radiations; (D) The binding of specific ligands to the receptors mediating the
endocytosis (e.g., transferrin and insulin receptors) allows the uptake of large compounds and NPs
conveniently functionalized. By a subsequent exocytosis process, vesicles can then release their content
at the abluminal side (RMT); (E) If the compound has sufficient cationic charge, it can induce a localized
electrostatic disruption of membrane phospholipids resulting in the so-called Adsorptive-Mediated
Transcytosis (AMT); (F) If the drug is carried by NPs exhibiting magnetic properties (such as IONs) a
localized magnetic field, generated by an external electromagnet, can be used to produce a driving
force enabling the passage of such NPs from the bloodstream to a targeted region of the brain (through
both paracellular and transcellular routes).
RMT generally works for large peptides and proteins (>600 Da); examples are the processes of
endocytosis triggered by insulin and transferrin receptors [6]. CMT generally allows smaller nutrient
molecules (<500 Da) crossing the barrier; examples are the transporter for glucose, amino acids,
nucleosides and choline. AMT takes place when a positively charged compound is able to induce a
pronoun d nd localized disruption of plasma-membrane integrity; exampl s are cationized albumin
or syntheti NPs coated with molecul s such as chitosan.
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Notably, to date, the only drugs actually capable of crossing the BBB in therapeutic concentrations
are small lipophilic molecules (<500 Da) used in the treatment of CNS diseases, especially in psychiatric
disorders. Many other potentially useful drugs cannot be used unless new strategies to overcome the
BBB are devised, possibly exploiting the physiological mechanisms previously listed (in particular
CMT and RMT) by coatings able to mimic the ligand-protein interactions.
In addition, a number of non-invasive and effective strategies to loosen tight junctions and thus
induce a transient increase in BBB permeability have been recently developed, possibly enabling
macromolecules to enter the CNS via paracellular route. In particular, Focused Ultrasound (FU) used
to induce mechanical stress at cellular level can temporarily disrupt tight junctions and represent one
the most promising approach. In this regard, at the Sunnybrook Research Institute (Toronto, ON,
Canada), O’Reilly and colleagues have employed low-frequency FUS to safely open the BBB in half of
the brain of aged dogs [86]. They succeeded in increasing BBB’s permeability by about 20% with no
evidence of tissue damage in all animals tested.
Temporary osmotic opening of BBB (e.g., by mannitol infusion [32]) is another proven technique
to increase BBB permeability. Although this method has been controversial for decades because of the
variability of its outcomes, recent developments that take advantage of arterial microcatheterization
and MRI guidance techniques have made it super-selective, more reliable and predictable [87].
Moreover, adenosine-mediated BBB modulation is another recent and notable approach:
Adenosine receptor activation can indeed increase BBB permeability, while the antagonism of its
signaling has been reported to tighten junctions between endothelial cells in both in vivo and in vitro
models [88].
Other possibilities to bypass the barrier include the intranasal administration [89] or the
opportunistic delivery, when taking advantage of particular situations, such as tumors, inflammatory
and infectious sites where the BBB permeability is enhanced as consequence of the leaky vasculature
of the affected tissues.
In the sections below, we will focus on those MNP applications allowing a nondestructive BBB
crossing (see Table 1): Essentially the use of magnetic fields to facilitate the passage of drugs by
mechanical-driven magnetic carriers or to increment BBB permeability by magnetic heating.
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Table 1. MNPs Blood Brain Barrier applications.
IONs MNPs Magnetic Mechanism Model Effect Preparation Toxicity Ref.
Fe3O4
PEGylated fluorescent liposomes +
Transferrin
Diameter = 130 nm
Static 0.08 T
24 h
Transferrin (RMT) +
magnetic force
promote crossing
In vitro BBB human
endothelium +
astrocytes
+50–100% transmigration
2 pg Fe/cell uptake
Coprecipitation
aqueous
2 h stability
TEER and cell
viability unchanged
at 48 h
[26]
Fe3O4
Polysorbate 80
Diameter = 11 nm (hydro 29 nm)
ζ = 19 mV
Static 0.3 T
2 h
Poly adsorb protein
(RMT) + magnetic
force promote
crossing
In vivo rat BBB
Accumulation in near
cortex
0.6 mg Fe/g tissue uptake
9-fold increase
Mixing 0.2 g Tween
80 with 0.4 PEG IONs
Cell viability
unchanged at 72 h [27]
Fe3O4
Silica-coated nanocapsule
Diameter = 100–150 nm
Ms = 5-fold SPION
Static 1000 Oe
1 week
RF (100 MHz)
Cell membrane
translocation In vivo mice BBB
25-fold increased
concentration
Emulsion
polymerization
Slight reversible
astrogliosis
No immunotoxicity
[28]
Fe3O4
Gold coated
Diameter = 25–40 nm
Ms = 30 emu/g
Static 0.01 T
6 h
Accumulation by
magnetic force
In vitro human
CSFBB + in vivo rat
CSFBB
Up to 50% MRI signal
difference confirmed
local histological
accumulation
Coprecipitation
aqueous High cell viability [29,34]
Fe3O4
BDNF binded
Diameter = 60 nm
Weak static
magnet
exposition
Magnetic force
In vitro BBB human
endothelium +
astrocytes
73% BDNF cross 3.5-fold
increase
Suppress apoptosis
Spine loss reversed
Coprecipitation High cell viabilityand TEER unchanged [30]
Fe2O3
Oleic acid coated
Diameter = 220–250 nm
ζ = −4 to −17 mV
Static 8000
Gauss
Passive diffusion or
RMT + magnetic force In vivo rats
Indocyanine green load
increased brain
concentration 5% tot dose
Thermal
decomposition - [31]
Fe3O4
Aminosilane or EDT coating
Diameter = hydro 25 or 29 nm
ζ = 21 or −39 mV
Static 0.06–0.1 T
24 h
Improve
concentration after
mannitol opening
BBB
In vitro mice
endothelium
Flux increase to 44% for
EDT after osmotic
opening
Aqueous phase
reduction/hydrolysis
No change in
permeability [32]
Fe3O4
Lipophilic fluorescence dye
covered by α-D-glucose units
Ms = 350 kA/m
Diameter = hydro 117 nm
ζ = −17 mV
Static
5 h Magnetic force
In vitro BBB human
endothelium + rat
astroglia
11, 8, and 29 fold uptake
increase of 35, 70, and
140 µg/mL
-
TEER and cell
viability unchanged
at 29 h
[33]
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Table 1. Cont.
IONs MNPs Magnetic Mechanism Model Effect Preparation Toxicity Ref.
Fe3O4
Amphotericin B magnetic
liposomes
Diameter = 240 nm
Ms = 32 memu/g
Static Magnetic force In vivo rats
Histological
accumulation 400 ng/g
brain (after 30 min)
Film dispersion–
ultrasonication
Reduced death with
magnetic field [35]
Fe3O4
Cationic polymeric liposome
Diameter = 20 nm
Static
0.5 T Magnetic force In vivo rats
Paclitaxel concentration
3-fold histological
accumulation
Thin-layer
evaporation - [36]
Fe3O4
SiO2-coated+Amino Tat peptide
Diameter = 100 nm
ζ = 42 mV
Ms = 19 emu/g
Static
2 h
Magnetic force +
transport Tat
In vitro BBB human
endothelium +
glioma
Cell internalization
2.6-fold increase
Permeability 2.3-fold
increase
Alkaline
co-precipitation
TEER moderate
decrease
High cell viability
[37]
Fe3O4
Cross-linked poly(ethylene
glycol)-poly(aspartate) or
citrate-coated
Diameter = 25 nm or 90 nm
Alternate
33.4 kA/m at
300 kHz
Temperature opening
BBB
In vitro mice or
dogs
2–3 -fold flux increase
3-fold cell uptake
increase
Co-precipitation No cell death [38]
Fe3O4
Poly(maleic acid-co-olefin) coated
Diameter = 11–13 nm
Alternate
7.6 kA/m at
150 kHz
Temperature opening
BBB In vivo rats
Histological
accumulation only
after RF
-
Reversibility of
opening
No brain immune
response
[43]
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4.4. In Vitro and In Vivo Evidence of BBB Trespassing by MNPs under Static Magnetic Fields
In vitro studies were mainly performed by administrating MNPs of different size and
characteristics to in vitro BBB models obtained by co-culturing endothelial cells and astrocytes in
the presence of static magnetic fields.
In [33] Brain Capillary Endothelial Cells (BCECs) were first stained for the tight junction
protein ZO-1 and then incubated with IONs at different doses (35, 70 and 140 µg/mL) for 24 h,
showing that internalization and transcellular transport occurred also in the absence of magnetic
fields and without exerting any toxic effect. By adding a magnetic force produced by a ferrite block
magnet and corresponding to B = 0.39 T, the BCEC monolayer did not lose its integrity (the initial
TEER = 43.2 ± 0.5 Ω·cm2 was unchanged after 5 h incubation with IONs and also after 5 h exposure
to B). The passage of IONs across the BCEC monolayer was concentration-dependent and was
significantly increased by B at all concentrations (11-fold at 35 µg/mL, 8-fold at 70 µg/mL and 29-fold
at 140 µg/mL). Finally, after having crossed the endothelial monolayer, nanoparticles entered the
‘brain side’ of the barrier and fluorescent IONs could be detected in the co-cultured astrocytes, even at
remote distance.
Therefore, IONs proved able to:
• pass the BBB in the field direction,
• not modify the TEER (i.e., no damages to the barrier integrity),
• not alter the cell viability,
• be internalized by astrocytes.
Similar conclusions have been reported by different groups using in vitro BBB models with
different MNP formulations and magnetic field intensities [26,30]. Another interesting application of
magnetic driving has been proposed in [34] for intrathecal drug targeting in the CNS: here Venugopal
and colleagues used SMF to target gold-coated magnetite NPs to specific regions along the spine,
employing both in vitro and in vivo models. The gold coating served to prevent oxidation and assure
the biocompatibility of the MNPs, whose overall diameter was between 25 and 40 nm. First, a human
spine phantom was prepared, to simulate the administration on MNPs in the CSF of the subarachnoid
space under magnetic driving. The optimal settings for the magnet placement and field strength were
investigated in order to drive the MNPs at specific spinal levels. Experiments were then repeated
on Sprague-Dawley rats, performing the injection of 20 µL solution of MNPs (17 µg/mL) in the CSF
between L4 and L5 vertebrae and placing a small magnet (0.01 T) in different positions between T9
and T1 vertebrae. Animals were imaged with 9.4 T MRI and later by histology, showing that magnetic
steering was very effective in localizing the MNPs in specific regions of the spine, without any evidence
of toxicity. The same group has proposed an implant-assisted intra-thecal magnetic drug targeting
system [29]. Promising results in MNP targeting have been reported also in the brain cortex of the
same animals and in other animal models as well [27,28,30,31,35–37].
4.5. Heating of MNPs by AMF: Applications for Increasing BBB Permeability and Drug Delivery
The magnetic moment of a MNP can only be oriented along two stable directions antiparallel to
each other and separated by an energy gap ∆E that for IONs is comparable to thermal energy. In the
absence of any external magnetic field, this results in a total magnetization that fluctuates randomly.
On the contrary, the application of an external AMF to MNPs reorients their magnetic moments and
produces heat.
In multidomain ferromagnetic materials the production of heat is due to hysteresis losses; in single
domain materials, as superparamagnetic IONs, the external magnetic field causes the rotation of the
magnetic moments, but this excitation is rapidly dissipated when the particle moments relax to their
equilibrium orientations. The Néel relaxation time tN associated to this phenomenon is:
tN = t0e
∆E
kT , (5)
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where t0 (whose value typically ranges between 10−9 and 10−10 s depending on the material) is the
so-called attempt time, T is the absolute temperature and k is the Boltzmann constant.
Another heating mechanism is possibly due to the rotational Brownian motion that creates
frictional losses into the surrounding environment. The Brown relaxation time is:
tB =
ηpir3H
4kT
. (6)
A general effective time of relaxation te f f comes from the combination of (5) and (6):
1
te f f
=
1
tN
+
1
tB
. (7)
which phenomenon dominates depends on size, viscosity and magnetic properties of the materials.
In general, for IONs, Néel relaxation predominates.
As a consequence, IONs can heat in presence of an AMF (up to 45 ◦C) and can be employed for
thermotherapy or for inducing a reversible increase in BBB permeability, involving both the paracellular
pathway (loosening of BBB’s tight junctions) and the transcellular one. At high AMF frequencies,
the heat generated is such (reaching t > 42 ◦C) as to damage cells and tissues, while the heat produced
by low frequencies is enough (t ~39 ◦C) to enhance BBB permeability without perturbing other brain
cells [6].
Such effect was monitored in vitro by Dan et al. [38] (bEnd.3 and MDCK-II cell lines, seeded
on Transwell filters and exposed to a 33.4 kA/m AMF at a frequency of 300 kHz) and in vivo by
Tabatabaei et al. [43] (using Evans Blue fluorescent dye to test the permeability of brain capillaries in
rats induced by a 7.6 kA/m field at 150 kHz).
One of the main goals of this approach is obviously that of overcoming the BBB for loading drugs
to CNS. In this regard, Do and colleagues [71] investigated the guidance of magnetic nanocontainers
that can potentially carry therapeutic substances across the BBB (specifically fluorescent carboxyl
magnetic particles, 700–900 nm in diameter) using both direct current (DC) and alternate current (AC)
electromagnetic driving systems. A two-coil electromagnetic actuator was developed to steer the
MNPs in the desired direction operating on the input current (between 1 and 3 A) and produce a
magnetic field ranging between 28.1 and 79.8 mT with gradients between 0.43 and 1.39 T/m. Mice were
injected with 0.4 mL of saline solution containing fluorescent MNPs and were treated without or with
DC and AC magnetic fields of different strength for 1 min. Brain tissue was then sliced and evaluated
with confocal microscopy images, showing that there was no significant accumulation of MNPs in the
absence of magnetic field. The uptake was increased in DC configuration, but higher magnetic forces
corresponded to an increased aggregation of the particles. Under AC conditions not only the trans-BBB
transport was larger than at the corresponding DC values, but MNP aggregation was avoided.
This result may be of interest for optimizing the processes of electroporation, e.g., for gene
delivery or anti-HIV drug applications. Similarly, in [41] nanoelectroporation of therapeutic cargoes
was investigated using magneto-electric nanoparticles made of BaTiO3 and CoFe2O4, with an average
size of 25 nm, which showed to be biocompatible on microglia cultured on a gold chip, at doses <50 µg
for 106 cells. Particle accumulation in microglia was observed when an AC-magnetic field of strength
ranging between 40 and 80 Oe was applied. Interestingly, different phenomena were observed at a
range of field strengths, i.e., a more superficial accumulation at lower field, which tended to interest
the deeper layers when field intensity was increased (although also toxicity due to heat generation
was greater).
Finally, the heating of MNPs can also be used as an externally controlled trigger of the loaded drug
release. The thermal energy can be used indeed to open the gates for any kind of organic or inorganic
carriers (e.g., thermoresponsive nanogels) and AMF can provide fully reversible and controllable
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transmission of this energy [9]. In particular, AMF have been demonstrated to be capable of an accurate
time control of the release of different drugs in different in vitro models [39,40,42].
4.6. Magnetofection and CNS
Magnetofection is defined as the delivery of genetic material (with viral or non-viral vectors),
usually performed in vitro by means of an high-field/high-gradient magnet placed underneath the well
culture plate where the cells are growing. The in vivo applicability of the technique is still uncertain.
Magnetofection shows significant advantages over traditional transfection methods (up to 50×
increase in transfection levels), including reduced process time (10 min vs. 2–4 h), higher success rates
with lower vector doses, preservation of the cells membranes with high post-transfection viability [9].
The method was developed by Christian Plank and collaborators [90] for gene transfer in cell
cultures and in vivo using MNPs or MNP-viral complexes conjugated with DNA.
Improvements have been observed by using oscillating magnet field under the plate or
perpendicular to the magnetization vector. This mechanical stimulation promotes more efficient
endocytosis and increases transfection efficiency [44].
Neurons are particularly sensitive to cytotoxicity and generally difficult to transfect, there is
therefore a growing interest in developing MNP formulations and magnetofection protocols suitable
for neuronal cell cultures [45,46,48]. Gene transfer to the CNS poses significant challenges due to both
the relative inaccessibility of the brain and the extraordinary complexity of CNS structures. On the
other hand, this approach offers unique advantages for the long-term delivery of neurotrophic factors
to specific CNS regions.
The technology for magnetic field-assisted gene delivery has now advanced to a point from where
it seems feasible to implement minimally invasive gene therapy strategies for the brain in vivo [16,47,49].
4.7. MNP Biomedical Applications
MNP targeted administration showed promising results in many different CNS diseases
(see Table 2). For instance, in brain tumors, they enhanced chemotherapy efficacy [53], and were
found to be useful to deliver gene therapy [51] or as nanosurgeons using mechanical force to destroy
malignant cells [50,52].
In particular, Chertok et al. used 110 nm nanoparticles with an iron oxide core and a starch coating
to target a brain tumor in an in vivo model of glioma (rats harboring orthotopic 9 L-gliosarcomas) [91].
In this work, they showed that magnetic targeting significantly enhanced the accumulation of MNPs
in gliosarcomas. Interestingly, in that case, the problem of passing the BBB was partially mitigated
since the glioma typically implies structural endothelial abnormalities that make tumor vasculature
more leaky and permeable. Notably, the same pathological alterations in brain tumor microcirculation
could be used to discriminate the diseased site from healthy brain [84].
Wang et al. [92] successfully co-loaded magnetic liposomes with both drug and gene to treat
glioblastoma in a rat model. This multifunctional approach to nanocarriers is of particular interest
because it represents a first step towards the design of a new class of “smart” MNPs (see Section 5).
MNPs can be helpful also in anti-HIV therapy. Being the brain one of the main sources of
virus production to the periphery, a low delivery of anti-retroviral drugs across the BBB prevents
the complete eradication of HIV from the body. Magnetic nanocarriers can be used to target hidden
latent virus in the brain, but also to treat the neurological disorders caused by HIV damage to the
CNS (neuroAIDS), consisting in neurocognitive impairment and HIV-associated dementia. Specifically,
nanocarriers were used in vitro for delivering anti-HIV drugs to reduce infection levels and oxidative
stress, but also to regulate synaptic activity and recover spine density [54–59].
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Table 2. MNPs biomedical applications.
MNPs Magnetic Mechanism Model Results Toxicity Ref.
Au + Ni80Fe20 (permalloy)
1 µm radius disk-shaped
Dynamic
1 T at 20 Hz rotating Vortex shaped rotation In vivo mice glioma Increased survival
No change in histology
No side effects [50]
pEGFP/p53 conjugated Static Gene therapy + magnetofection In vitro BBB +glioblastoma
Increased induced
apoptosis - [51]
Aptamer conjugated dextran
coated
Alternate
9.55 kA/m at 1 Hz 3D Rotating nanosurgeons In vitro glioblastoma
Increased induced
apoptosis - [52]
Octadecyl-quaternized
carboxymethyl chitosan Static 0.5 T Delivery loaded paclitaxel In vivo rats glioma
Increased survival
Prolonged bioavailability Reduced side-effects [53]
Inhibitor of metalloproteinase-1
conjugated Static 0.8 T
Crossing BBB and regulation of
metalloproteinases
In vitro BBB + HIV
infection
Recovery in spine density
ROS and HIV infection
level decrease
Unchanged TEER and
cells viability [54]
Bilayers:
Tenofovir + dextran
Sulphate + vorinostat
Static 0.08 T
6 h
Crossing BBB and
antiretroviral therapy
In vitro BBB + HIV
infection
HIV infection level
decrease
Prolonged bioavailability
Unchanged TEER and
cells viability [55]
Azidothymidine 5′-triphosphate
loaded CoFe2O4@BaTiO3
Static 22 Oe/cm
6 h
Alternate
66 Oe at 100 Hz
5 min
Crossing BBB and controlled
release of antiviral drug
In vitro BBB + HIV
infection
Functional and structural
integrity of the drug after
the release
High cell viability [56]
Beclin1 siRNA binded
CoFe2O4@BaTiO3
Static 0.8 T
3 h
Crossing BBB and regulate
autophagy
In vitro BBB + HIV
infection
Attenuate HIV-1 replication
and viral-induced
inflammation
Unchanged TEER and
occludin expression [57]
Morphine antagonist, CTOP
conjugated Static 0.5 T
Crossing BBB and drug
delivery
In vitro BBB + HIV
infection
Recovery in spine density
Prevention of morphine
induced apoptosis
High cell viability
Unchanged TEER [59]
PEG shell Alternate15 kA/m 500 KHz
Heat-sensitive capsaicin
receptor TRPV1 activated by
magnetothermal genetic
stimulation
In vitro neurons +
in vivo mice
On demand activation of
neurons in deep nuclei
(VTA)
Lower glial activation
and macrophage
accumulation compared
to implant
[60]
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Table 2. Cont.
MNPs Magnetic Mechanism Model Results Toxicity Ref.
CoFe2O4-BaTiO3 GMO coated
Static 3000 Oe/cm
Alternate
100 Oe at 0–20 Hz
Crossing and concentrate in
brain then modulate neural
activity
In vitro + in vivo
mice
EEG detectable modulation
activity of 1 mV
No toxicity for astrocytes
and blood cells in vitro [61]
Co-ferrite core and Mn-ferrite shell
Polymer PMA coated
Alternate
7–30 kA/m at
412–570 KHz
Heat-sensitive capsaicin
receptor TRPV1 activated by
magnetothermal genetic
stimulation
In vitro neurons +
in vivo mice
On demand evoked motor
cortex ambulation, striatum
rotation or freezing
- [62]
GFP-tagged ferritin Alternate23–31 mT at 465 kHz
Heat-sensitive capsaicin
receptor TRPV1 activated by
magnetothermal genetic
stimulation
In vitro neurons +
in vivo mice
Glucose-sensing
hypothalamus neurons
modulate feed behavior
- [63]
Starch-coated Static 150 mT Magnetic force open neuronchannels In vitro neuron
Mechanical opening of
N-type mechanosensitive
Ca2+ channels
Reversibility of opening [65]
Starch and chitosan coated Static 150 mT Magnetic force open neuronchannels In vitro neuron
Mechanical opening of
N-type mechanosensitive
Ca2+ channels
Unchanged cell viability,
reversibility of opening [66]
Ferumoxide-labeled human neural
stem cells Static 0.32 T Magnetic targeting In vivo stroke rats
Better targeting and
recovery in a stroke model
Unchanged
differentiation into
neurons or astrocytes
[68,69]
Dextran-coated
Alternate
1–6 A at 0.25–2 Hz
10 min
Osmotin load targeting in
hippocampus and delivery
In vitro + in vivo
AD rats
Memory improvement
Reduced protein
accumulation and
synaptotoxicity
Unchanged viability
No apoptosis
No BBB leakage
[70,71]
Oleic acid-coated 3 days
Gene therapy delivery
Alpha-Synuclein RNAi
Plasmid
In vitro + in vivo
PD mice
Motor improvement
Reduced
neurodegeneration
No organ damage
Normal blood test
12 days
[73]
Uncoated Fe3O4
Alternate
2 h/d for 1 week
Synergic effect of magnetic
stimulation and MNPs In vivo PD rats
Motor
improvement/recover
feeding behavior
Reduced ROS and lesion
volume
Normal mitochondrial
activity [74]
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By introducing heat-sensitive capsaicin receptors into nerve cells and then injecting MNPs into
specific brain regions it is possible to control the activation of specific neural activity [60,65] or gene
expression evoking specific behaviors in animal models, provided AFM is applied [62,63]. This opens
to the possibility to develop a wireless Deep Brain Stimulation (DBS) [64,67], an application potentially
valuable for many CNS diseases (e.g., NDs). Notably, a successful modulation of brain activity in
mice by injecting MNPs into the blood circulation and forcing them to cross the BBB has also been
reported [61].
Moreover, MNPs can be used in stroke to deliver neural stem cells [68,69], and can offer a new
strategy for drug delivery in NDs [75] such as Alzheimer’s [70–72] or Parkinson’s disease [73,74].
In particular, by using pulsed magnetic fields, Amin and coworkers [70] succeeded in drive
dextran-coated Fe3O4 MNPs loaded with osmotin to the brains of Aβ1–42-treated mice. After osmotin
delivery, they measured an attenuation of Aβ1–42-induced synaptic deficits, Aβ accumulation, tau
hyperphosphorylation, and BACE-1 expression.
The use of magnetic resonance has been proposed to drive and image in real time MNPs in deep
tissues trying to maximize the target focusing, since the high magnetic field (>1.5 T) allows IONs to
achieve magnetization saturation near deep targets [9]. However, traditional MRI scanners are not
optimized for particle driving and need to be customized or, at least, upgraded with additional steering
coils [93,94]. As a result, while this approach has been essentially presented as a proof-of-concept
application, research is still ongoing to create a new effective platform being capable of interleaving
imaging and targeting to enable real-time image-guidance of MNPs [18]. In general, while precision
feedback control of a single magnetic particle has already been demonstrated in animals and in patients,
the gathering of a large number of MNPs in a small and precise area of the CNS has proved to be more
difficult [18].
Magnetic Particle Imaging (MPI) is an innovative technique which uses the nonlinear magnetic
response of MNPs under strong (>3 T/m) magnetic field gradients. MPI has the potential of imaging
MNPs with high spatial and temporal resolution. In particular, the spatial resolution of MPI (and also
of MRI) could be improved with a dedicated hardware (currently still under development) able to
create ultra-fast magnetic pulses (e.g., with rise times of less than 10 µs) that can overcome the effect of
peripheral nerve stimulation [18].
Animal and in silico modeling should be used together to design and project the most appropriate
MNPs for different clinical indications. In general, an in vivo real-time imaging and targeting of MNPs
is the major goal to be pursued [18].
4.8. Safety and Toxicity of MNPs
Conflicting results have been reported for NP toxicity and more accurate studies are
mandatory [76], especially in the context of MNPs and IONs, where the chronic effects have received
low attention [78] up to now.
NPs are generally eliminated by metabolic pathways and a large fraction of them is captured
by the reticuloendothelial system (monocytes and macrophages), but metal NPs have been shown to
be particularly critical for brain and BBB as they can induce neurotoxicity, neuroinflammation and
permanently alter the BBB permeability [76].
In particular, iron homeostasis is an important process both at a general body level and is involved
in DNA synthesis, mitochondrial respiration, oxygen transport. It is also involved at the CNS level
in metabolic processes, myelin synthesis and neurotransmitter synthesis. ION administration could
interact and possibly alter these processes [79] causing the upregulation of proteins associated to
the cellular iron transport and storage and the downregulation of proteins associated to the cellular
iron uptake. Iron accumulation could change the cellular equilibrium producing more Reactive
Oxygen Species (ROS) via Fenton’s reaction [79]. ROS would in turn cause oxidative stress promoting
protein aggregation (e.g., Aβ in Alzheimer’s disease and α-synuclein in Parkinson’s disease) that can
contribute to neurodegeneration. CNS is particularly vulnerable to ROS and oxidative stress since
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there is less enzymatic activity against free radicals than in the rest of the body; moreover a high
iron level could inhibit the occludin expression, a protein essential for tight junction integrity, thus
leading to a BBB damage [79]. Iron accumulation and neurotoxicity critically depend on the MNP
characteristics, in particular, their persistence in the system, which is generally appreciated for the
improved pharmacodynamics properties, but could also worsen the toxic effects [79]. The surface
charge is another important characteristic as high concentration of anionic or cationic NPs can affect
the neurovascular unit compromising the BBB effectiveness [76]. In particular, ION uptake from the
glial cells seems to be larger if compared to other CNS cells so they could be more sensitive to the toxic
effects [79].
Degradation by macrophages is very slow and iron is metabolized over 6–12 weeks [77] in a
dose-dependent manner, but partially retained in the epithelial cells of the choroid plexus and in the
neuroglial cells [77]. When neuronal cells are exposed to IONs, however, some adaptation to local iron
content occurs by downregulating the correspondent receptors [79]. Favorable properties were also
detected: the formation of a protein corona around the NPs [77], able to alter their chemico-physical
properties and improve the transport across the BBB [76] and the uptake by monocytes was of
special interest.
Finally, it is worth reporting that some ION-based contrast agents had already been developed
in the 1990s [95,96] and the adverse effects connected with their administration are well described
in literature. More recently, in the USA the marketed anti-anemic drug ferumoxytol (Feraheme™,
AMAG Pharmaceuticals), composed by IONs with strong T1 and T2 relaxivities, has been used
off-label for MR imaging, while in Europe a similar compound (ferumoxtran-10 Sinerem® (in the
EU, Guerbet S.L.)/Combidex® (in the US, AMAG Pharmaceuticals)) is gaining popularity among
a new generation of radiologists [77]. Such clinical experiences shed new light on the secondary
toxic effects, fully reported by [77]. In addition to the severe anaphylactic reactions to intravenously
administered ferumoxytol NPs, also immune responses of the Gell-Coombs system, non-immune
reactions (such as the complement activation-related pseudoallergy) and long-lasting skin discoloration
were reported [77].
5. Challenges and Future Perspectives
As reported in the previous sections, there are numerous papers in the recent scientific literature
reporting successes in the field of magnetic targeting and of MNP-mediated BBB crossing and drug
delivery, but none go beyond the proof-of-concept level. In the past decades, MNPs (especially
IONs) have been generally regarded as one of the most promising theranostic tools, but in the case
of biomedical applications, it should be noted that, until now, most of the in vivo studies have been
restricted to animal models (and therefore to small organisms) and there are very few clinical trials.
Moreover, to date, no commercial applications of magnetic targeting in human can be found and the
only truly marketed clinical application of MNPs consisted of IONs used as enhanced contrast agents
in the field of NMR (Feridex® (in the US, Berlex Laboratories)/Endorem™ (in the EU, Guerbet S.L.),
Resovist® (in the EU and Japan, Bayer Healhcare)/Cliavist™ (in the EU), Sinerem®/Combidex®, etc.).
The main challenge in this field appears to be that of moving from the lab environment to the
clinical setting. More into details, the precise and deep focusing of magnetic fields for the controlled
targeting of drug-releasing nanocarriers in human tissue should be pursued (see e.g., [70]). Some of
the reasons that make this goal so difficult are essential and specific technical sub-challenges and are
here briefly summarized.
The first hurdle is the fact that the field strength rapidly diminishes with target depth in the body.
This problem is of particular relevance when moving from small animal in vivo studies to human
clinical applications [9,18].
Earnshaw’s theorem (see Section 4.2), which establishes the impossibility of creating a magnetic
trap just by using static magnetic fields, is the second limitation. For this reason, magnetic focusing
systems need to be though in terms of dynamic fields and their space- and time-averaged values.
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The third major complication is the need of driving a large number of magnetic objects to get
any measurable therapeutic result. If it is proved that the single MNP can be effectively targeted with
high precision and a good feedback control [18], the use of dynamic fields affects the focalization
capability when dealing with a large number of MNPs. This is due to the fact that while one particle is
driven toward its target, the same (alternating) magnetic field may drive another particle away from
the target.
Another challenge in the clinical use of MNPs is their poor retention upon removal of the external
magnetic field, thus severely impinging on particle/drug uptake [9]. In this regard, searching for some
strategy to speed up the internalization processes seems to be key to avoid more invasive alternatives
(e.g., surgical implantation of a magnet in the proximity of the body district of interest). The need to
control the uptake rate and the local availability of injected MNPs is even greater when the target is
within the CNS, because of the presence of the BBB.
In addition, despite the many above mentioned promising techniques allowing to increase the
BBB permeability—and the proved capability of steering MNPs across the barrier—the search for
increasingly effective and safe methodologies to control its selectivity and ensure its recovery after
drug delivery remains a crucial issue from a clinical point of view.
A possibly less technical but more cultural challenge will possibly be the willingness to create
collaborative networks on specific topics within the wide scope of MNP biomedical applications.
Due to the intrinsically interdisciplinary nature of this field, only by combining expertise coming from
different disciplines, according to a real translational approach, will allow to achieve the main goal
stated above. Starting from a specific disease, a taskforce including physicists, chemists, biologists,
pharmacologists, clinicians and engineers, integrating their knowledge and combining their efforts,
should be able to determine, among a virtually infinite number of combinations, the optimal parameter
values to solve that particular problem, that is to choose the best MNP type, dosage, functionalization,
drug cargo, driving/delivery hardware system, BBB crossing techniques, also accounting for the
bioavailability of the nanoparticles and the minimization of their toxicity.
This integrated approach is also the key to understand what is coming on. A new generation of
scanners able to implement a real-time imaging of MNPs interleaved with a strong external driving field
for steering them at the same time is likely to be soon available [18]. In addition, integrated hardware
devices dedicated to magnetic heating or FUS generation for BBB trespassing could accompany these
new all-in-one theranostic platforms.
Finally, new smart magnetic nanocarriers, combining different technologies and specifically
thought for CNS applications, are likely to be designed [92]. Their surface could be functionalized
with special molecules (or antibodies) able to bind specific receptors located at the luminal side of
brain capillaries in order to trigger transcytosis, while their core could be filled with genetic material
or multiple drugs that will be released only upon BBB crossing.
6. Conclusions
The peculiar properties of MNPs make them ideal for the physical targeting of CNS to optimize
drug delivery. In general, only small-sized NPs characterized by stringent surface properties can cross
the BBB. However, only a minority of the NPs developed so far has proven to be able to reach the
brain from the bloodstream. So, despite the fact that the study of the BBB—and the related search
for innovative methods to cross it—have been areas of intense research for many years, we are still
far from easily and safely controlling its permeability. For this reason, alternative strategies have
been adopted to bypass or temporarily disrupt the BBB. The magnetic driving via external steady
or alternate magnetic field has been explored as well and seems to be very promising for future
clinical applications.
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